The CDC genomic surveillance found that the XBB.1.5 variant has increased from causing 1% to over 40% in only a month.
This article first appeared on ContagionLive.com.
Omicron continues its reign as the dominant COVID-19 strain, and its new subvariant, XBB.1.5, is now most prevalent in the US.
As of the end of December 2022, the Centers for Disease Control and Prevention (CDC) genomic surveillance found that XBB.1.5 was responsible for 40.5% of new COVID-19 infections. In the American Northeast, the CDC estimates XBB.1.5 is causing 75% of new infections.
Omicron BQ.1.1 and BQ.1, previously the reigning variants, are responsible for 26.9% and 18.3% of new cases, respectively.
XBB.1.5 swept across the country rapidly, making up only 1% of new infections a mere month ago. The subvariant appears to be 5 times more infectious than earlier Omicron strains, which were already 5 times more infectious than the original, wild-type COVID-19 virus.
Recent holiday gatherings, resistance to immune system antibodies, and an improved ability to bind tightly to the body’s ACE-2 receptors all likely contributed to the explosion of XBB.1.5 infections.
Although the World Health Organization (WHO) stated XBB.1.5 has a “growth advantage” above prior subvariants, there is currently no indication it will cause more severe or fatal disease. So far, symptoms of XBB.1.5 are believed to be consistent with earlier Omicron strains.
So far, symptoms of XBB.1.5 are believed to be consistent with earlier Omicron strains.
XBB.1.5 isn’t expected to cause more severe disease than prior COVID-19 variants, but it is still essential to take all available precautions to avoid getting infected. The anticipated surge of XBB.1.5 infections will overburden the health system once again, and as we know, COVID-19 vaccines are less effective at preventing mild disease.
Fortunately, experts are confident that COVID-19 vaccines will remain an effective prevention strategy. Individuals who have received an updated bivalent COVID-19 booster will benefit from even more effective protection.
Pfizer’s antiviral, Paxlovid, also significantly reduces the risk of severe or fatal disease progression.
This story will be updated as we learn more about the XBB.1.5 COVID-19 variant.
CDC HICPAC Considers New Airborne Pathogen Guidelines Amid Growing Concerns
November 18th 2024The CDC HICPAC discussed updates to airborne pathogen guidelines, emphasizing the need for masks in health care. Despite risks, the committee resisted universal masking, highlighting other mitigation strategies
The Importance of Hand Hygiene in Clostridioides difficile Reduction
November 18th 2024Clostridioides difficile infections burden US healthcare. Electronic Hand Hygiene Monitoring (EHHMS) systems remind for soap and water. This study evaluates EHHMS effectiveness by comparing C difficile cases in 10 hospitals with CMS data, linking EHHMS use to reduced cases.
Breaking the Cycle: Long COVID's Impact and the Urgent Need for Preventative Measures
November 15th 2024Masking, clean air, and vaccinations are essential in combating COVID-19 and preventing long-term impacts, as evidence mounts of long COVID's significant economic, cognitive, and behavioral effects.
Our Understanding of Immune Issues Is Evolving: Here Are 5 Reasons Why
October 25th 2024The past 5 years in medicine have seen significant advances in RNA vaccines, understanding immune dysregulation, and improved interspecialty communication, promising better disease eradication and tailored treatments.